Stockscreener 앱 받기
108.00
0.00%
0.00
시간 외 거래:
108.90
0.90
+0.83%
전일 마감가:
$108.00
열려 있는:
$108.61
하루 거래량:
11.95M
Relative Volume:
1.33
시가총액:
$136.94B
수익:
$28.73B
순이익/손실:
$5.97B
주가수익비율:
22.74
EPS:
4.75
순현금흐름:
$9.84B
1주 성능:
-1.19%
1개월 성능:
+5.37%
6개월 성능:
+19.09%
1년 성능:
+71.02%
1일 변동 폭
$107.19
$111.78
1주일 범위
$107.19
$112.09
52주 변동 폭
$64.86
$119.96
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
108.00 | 136.94B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
785.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
150.73 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
74.01 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.49 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.96 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - AP News
Gilead Sciences facility video - KTIV
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks
Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum
US approves Gilead's twice-yearly injection to prevent HIV - Citizen Tribune
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - proactiveinvestors.com
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - marketscreener.com
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
US FDA approves Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - statnews.com
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire
Buy, Sell, Or Hold GILD Stock? - Trefis
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company
Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Gilead lays off 36 people after axing Oceanside expansion plan - Fierce Biotech
Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating - TipRanks
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Jun 16 '25 |
Sale |
110.17 |
3,000 |
330,510 |
120,168 |
0.50%
1.29%
자본화:
|
볼륨(24시간):